Leticia Moreno-García

Mrs. Leticia Moreno-García

Department of Anatomy, Embryology and Animal Genetics, University of Zaragoza, Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED), Agroalimentary Institute of Aragon (IA2), Institute of Health Research of Aragon (IIS),
orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
LMLeticia Moreno-García
Leticia Moreno-García
TRTresa Iguázel López Royo
Tresa Iguázel López Royo
ACAna Cristina Calvo
Ana Cristina Calvo
JTJanne M. Toivonen
Janne M. Toivonen
MSMiriam de la Torre Sebastián
Miriam de la Torre Sebastián
COCharo Osta
Charo Osta
Protein aggregation is classically considered the main cause of neuronal death in neurodegenerative diseases (NDDs). However, increasing evidence suggests that alteration of RNA metabolism is a key factor in the etiopathogenesis of these complex disorders. Non-coding RNAs are the major contributor to the human transcriptome and are particularly abundant in the central nervous system, where they have been proposed to be involved in the onset and development of NDDs. Interestingly, some ncRNAs (such as lncRNAs, circRNAs and pseudogenes) share a common functionality in their ability to regulate gene expression by modulating miRNAs in a phenomenon known as the competing endogenous RNA mechanism. Moreover, ncRNAs are found in body fluids where their presence and concentration could serve as potential non-invasive biomarkers of NDDs. In this review, we summarize the ceRNA networks described in Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, amyotrophic lateral sclerosis and spinocerebellar ataxia type 7, and discuss their potential as biomarkers of these NDDs. Although numerous studies have been carried out, further research is needed to validate these complex interactions between RNAs and the alterations in RNA editing that could provide specific ceRNET profiles for neurodegenerative disorders, paving the way to a better understanding of these diseases.

Verified
Journal Article
Open access
PDF file
LMLeticia Moreno-García
Leticia Moreno-García
FMFrancisco Javier Miana-Mena
Francisco Javier Miana-Mena
LMLaura Moreno-Martinez
Laura Moreno-Martinez
MSMiriam de la Torre Sebastián
Miriam de la Torre Sebastián
CLChristian Lunetta
Christian Lunetta
COCharo Osta
Charo Osta
Since NLRP3 inflammasome plays a pivotal role in several neurodegenerative disorders, we hypothesized that levels of inflammasome components could help in diagnosis or prognosis of amyotrophic lateral sclerosis (ALS). Gene and protein expression was assayed by RT-PCR and Western blot. Spearman’s correlation coefficient was used to determine the linear correlation of transcriptional expression levels with longevity throughout disease progression in mice models. Kaplan-Meier analysis was performed to evaluate MCC950 effects (NLRP3 inhibitor) on lifespan of SOD1G93A mice. The results showed significant alterations in NLRP3 inflammasome gene and protein levels in the skeletal muscle of SOD1G93A mice. Spearman’s correlation coefficient revealed a positive association between Nlrp3 transcriptional levels in skeletal muscle and longevity of SOD1G93A mice (r = 0.506; p = 0.027). Accordingly, NLRP3 inactivation with MCC950 decreased the lifespan of mice. Furthermore, NLRP3 mRNA levels were significantly elevated in the blood of ALS patients compared to healthy controls (p = 0.03). In conclusion, NLRP3 could be involved in skeletal muscle pathogenesis of ALS, either through inflammasome or independently, and may play a dual role during disease progression. NLRP3 gene expression levels could be used as a biomarker to improve diagnosis and prognosis in skeletal muscle from animal models and also to support diagnosis in clinical practice with the blood of ALS patients.

24 August 2017 in Molecular Neurobiology
Verified
Journal Article
Closed access
PDF file
PLPilar Larrodé
Pilar Larrodé
ACAna Cristina Calvo
Ana Cristina Calvo
LMLaura Moreno-Martinez
Laura Moreno-Martinez
MSMiriam de la Torre Sebastián
Miriam de la Torre Sebastián
LMLeticia Moreno-García
Leticia Moreno-García
RORosario Osta
Rosario Osta

13 February 2025 in British Journal of Pharmacology
Verified
Journal Article
Open access
NGNúria Gaja-Capdevila
Núria Gaja-Capdevila
LMLaura Mosqueira-Martín
Laura Mosqueira-Martín
MHMireia Herrando-Grabulosa
Mireia Herrando-Grabulosa
LRLaura Rodriguez‐Gomez
Laura Rodriguez‐Gomez
KGKlaudia Gonzalez‐Imaz
Klaudia Gonzalez‐Imaz
FGFrancisco Gil-Bea
Francisco Gil-Bea
Background and Purpose: Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disease with limited treatment options. ALS pathogenesis involves intricate processes within motor neurons, characterized by dysregulated Ca2+ influx and buffering in early ALS‐affected motor neurones. This study proposes the modulation of ryanodine receptors (RyRs), key mediators of intracellular Ca2+, as a therapeutic target.Experimental Approach: A novel class of novel FKBP12 ligands that show activity as cytosolic calcium modulators through stabilizing RyR channel activity, were tested in the superoxide dismutase 1 (SOD1)G93A mouse model of ALS. Different outcomes were used to assess treatment efficacy, including electrophysiology, histopathology, neuromuscular function and survival.Key Results: Among the novel FKBP12 ligands, MP‐010 was chosen for its central nervous system availability and favourable in vitro pharmaco‐toxicological profile. Chronic administration of MP‐010 to SOD1G93A mice produced preservation of motor nerve conduction, with the 61‐mg·kg−1 dose significantly delaying the onset of motor impairment. This was accompanied by improved motor coordination, increased innervated endplates and significant preservation of motor neurones in the spinal cord of treated mice. Notably, MP‐010 treatment significantly extended lifespan by an average of 10 days compared to vehicle.Conclusions and Implications: FKBP12 ligands, particularly MP‐010, exhibit promising neuroprotective effects in ALS, highlighting their potential as novel therapeutic agents. Further investigations into the molecular mechanisms and clinical translatability of these compounds are needed for their application in ALS treatment.

23 July 2024 in Research Square
Verified
Preprint
Open access
PDF file
LMLeticia Moreno-García
Leticia Moreno-García
LMLaura Moreno-Martínez
Laura Moreno-Martínez
MTMiriam de la Torre
Miriam de la Torre
JSJon Schoorlemmer
Jon Schoorlemmer
SMSofía Macías-Redondo
Sofía Macías-Redondo
ACAna Cristina Calvo
Ana Cristina Calvo
The full text of this preprint has been withdrawn by the authors due to author disagreement with the posting of the preprint. Therefore, the authors do not wish this work to be cited as a reference. Questions should be directed to the corresponding author.